Physician profile
Sharyn Shepherd
NPI 1629591987
$3,102.26
in general payments reported to CMS, 2019-2025
41 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $186 · 2023: $875 · 2024: $420 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328 · Education: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.47 |
| Education | $466.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $314.72 | 2021-2025 | Talvey, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $275.98 | 2022-2025 | |
| Genzyme Corporation | $187.23 | 2022-2025 | |
| Celgene Corporation | $181.63 | 2024-2025 | Reblozyl, Pomalyst |
| Blueprint Medicines Corporation | $156.69 | 2024-2025 | Ayvakit |
| Astellas Pharma US INC | $132.07 | 2025 | Xtandi, Vyloy |
| Daiichi Sankyo INC. | $112.81 | 2023-2025 | Enhertu |
| Gilead Sciences, INC. | $112.16 | 2022-2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $110.94 | 2023-2025 | Tagrisso |
| Genentech USA, INC. | $110.54 | 2023-2025 | Polivy |
| Abbvie INC. | $103.57 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Myriad Genetic Laboratories, INC. | $94.25 | 2023 | Myrisk |
| Exelixis INC. | $76.87 | 2022-2025 | Cabometyx |
| Incyte Corporation | $73.99 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharyn Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.